NattoPharma enters Chinese market with new MenaQ7 launch

d5bdeb08-e8a9-4ece-b0d7-f0d4ed738c68articleimage.jpg

30 Nov 2017 --- NattoPharma has participated in a launching conference commemorating the first product introduced in China featuring MenaQ7 Vitamin K2 as MK-7. During the event, FishBurg, a Chinese dietary supplement producer in the calcium/vitamin D3 (VD3) segment, signed a partnership and supply agreement with NattoPharma and officially launched its new Blue Hat-registered calcium/VD3/MenaQ7 Vitamin K2 supplement for bone health to the Chinese market.

The event was attended by 150 distributors from all across China who will promote the new FishBurg product via pharmacies and other Chinese dietary supplement channels. During the event, FishBurg, NattoPharma and the Norwegian council made presentations that marked the start of the important partnership and entry into the Chinese market.

The event culminated with the signing of the strategic partnership and supply agreement between FishBurg and NattoPharma. There was then a ribbon-cutting ceremony.

“With a population of 1.4 billion – particularly with the middle class somewhere in the neighborhood of 400 million – China represents significant market opportunity,” Daniel Rosenbaum, CEO of NattoPharma, tells NutritionInsight. “The importance of bone and cardiovascular health is a global concern, and a growing concern in China. As awareness of how Vitamin K2, and specifically MenaQ7 Vitamin K2 as MK-7, increases, it is clear we can play an important role in improving health of Chinese people.”

“The product launch is a clear indication of the commitment from both parties,” says Rosenbaum. “The event created excitement around MenaQ7 Vitamin K2, which has amazing market potential in China.”

Addressing the Chinese market’s challenges, Rosenbaum notes that NattoPharma is not competing directly with Chinese Medicine (TCM): “There is a long tradition of alternative therapies, including supplements and TCM, to improve health and wellness, so we see our efforts as complementary.”

“There is a fairly rigorous registration process in China, so as a company with strong clinical foundation for our high-quality material, this helps to distinguish us in the Chinese market,” Rosenbaum adds. “For example, it was clear with the FishBurg launch that our clinical data and continued commitment to clinical research were important factors for this outstanding company choosing us as their partner.”

The launch event was hosted by NattoPharma’s Chinese distributor partner Prochin, one of the first foreign enterprises set up in the Shanghai Free Trade Zone, focused on Food Ingredients, and one of China’s importers of dairy-based specialty ingredients. According to Jordan Yang, the commercial director of Prochin, distributors were excited to learn about MenaQ7’s arrival in China.

“FishBurg is quite confident that the newly launched calcium/VD3/MenaQ7 Vitamin K2 product will have a very impressive impact on the Chinese nutritional market, bringing the benefits of bone and cardiovascular health to all customers,” says Youwen Chen, the CEO of FishBurg.

“Not only does NattoPharma actively engage the media to help spread the word about the benefits of Vitamin K2, but we work hand-in-hand with our partners to help educate their specific markets and customers” Rosenberg adds. “For example, our Chief Medical Officer has just completed a tour through different countries in southeast Asia talking to practitioners and brand owners.”

In other recent news about NattoPharma’s MenaQ7 Vitamin K2, researchers have discovered that it could be a novel therapeutic target for calcific aortic valve stenosis (CAVS). NattoPharma has also successfully secured patents in Israel, the US and Australia for its “nature-identical synthesis” creating MenaQ7 PharmaPure Vitamin K2 as MK-7, adding further to the company’s patent portfolio.

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Health & Nutrition News

Sodium guidelines under scrutiny: Only regions consuming over 5g a day should be targeted, concludes study

10 Aug 2018 --- A new study shows that for the vast majority of communities, sodium consumption is not associated with an increase in health risks except for those whose average consumption exceeds 5g/day (equivalent to 12.5g of salt, or 2.5 teaspoons). Communities with high average levels of sodium intake (above 5g/day) were mostly seen in China, with only about 15% of communities outside China exceeding this level of consumption. 

Regulatory News

DSM pursues biotin patent suit against China’s Anhui Tiger

07 Aug 2018 --- DSM is pursuing a patent infringement lawsuit in China against a competitor for what it calls the “misappropriation of intellectual property” pertaining to the production of a key ingredient of Biotin (also known as Vitamin B7 or Vitamin H). On August 2, 2018, DSM IP Assets BV and two related operating group companies, DSM Vitamins (Shanghai) Ltd. and DSM Vitamins Trading (Shanghai) Ltd. served a suit against Anhui Tiger in China for patent infringement.

Health & Nutrition News

Premixes: Strong potential for plant-based nutritionals and protein innovation

07 Aug 2018 --- The aging of the population, increasing scientific evidence of the benefits of nutritional supplementation and the trend toward foods and beverages rather than pills and capsules have led to increased consumer interest in the incorporation of nutrient premixes to support a healthy diet. “Consumers are doing everything they can to stay healthy so that they can stay out of the traditional healthcare system,” says Sam Wright IV, CEO at The Wright Group, which develops custom nutrient premixes, the enrichment of rice and grains, as well as the microencapsulation of vitamins, minerals and omega 3.

Business News

DSM reports surge in Q2 profit boosted by “exceptional vitamin pricing environment”

01 Aug 2018 --- Specialty chemicals company DSM has reported a second-quarter core profit of €508 million (US$593.2 million), up 35 percent compared to Q2 2017, boosted by an “exceptional vitamin pricing environment” and cost cuts. The company has further confirmed its outlook for the full year, based on expectations of an Adjusted EBITDA growth towards 25 percent and a related higher ROCE growth.

Health & Nutrition News

Advancing human health and nutrition: DSM on the key trends driving its R&D 

31 Jul 2018 --- Thriving in today’s business environment requires not only financial success, but hinges on an awareness of social responsibility, taking into account local and individualized preferences and needs as well as consumer education. This is according to Jeremy Xu, President Human Nutrition & Health at DSM, who spoke with NutritionInsight about the company’s focus on human health and nutrition as well as the key trends informing its innovation cycle.

More Articles
URL : http://www.nutritioninsight.com:80/news/nattopharma-enters-chinese-market-with-new-menaq7-launch.html